Comparing long-term outcomes for partial and radical nephrectomy

Using the National Cancer Database, 3009 patients with low stage renal cell carcinoma (RCC) were identified as having undergone radical (2454 patients) or partial (555 patients) nephrectomy and were younger than 50 years. Median follow-up was 108.6 months during which 297 patients (12.1%) in the radical nephrectomy arm and 58 patients (10.5%) in the partial nephrectomy […]

read more

Outcomes following partial nephrectomy and percutaneous ablation for small renal masses

A study published in European Urology presents retrospective data from the Mayo Clinic in America regarding their experience with partial nephrectomy, percutaneous radiofrequency ablation (RFA) and percutaneous cryoablation for small renal masses (less than 4 cm, stage cT1). Long-term follow-up data from 1798 patients with primary cT1N0M0 renal tumours were treated with partial nephrectomy, RFA […]

read more

Role of stereotactic ablative radiotherapy for primary renal cell carcinoma

This paper reviews the use of stereotactic ablative radiotherapy (SABR) (also called stereotactic body radiotherapy, SBRT) for treating primary renal cell carcinoma (RCC) that cannot be removed with surgery. SABR is a treatment that automatically targets high doses of radiotherapy to the tumour with high precision. SABR is very accurate, and thereby maximises the cell-killing […]

read more

Role of stereotactic ablative radiotherapy (SABR) for kidney cancer

This systematic review and meta-analysis of the literature for the use of stereotactic ablative radiotherapy (SABR) for renal cell carcinoma (RCC), looks at data from 372 patients (383 tumours), most of whom were inoperable. The study concluded that renal SABR is effective locally and is well tolerated for primary RCC, despite treatment of larger tumours […]

read more

The role of cytoreductive nephrectomy in metastatic kidney cancer

Around 12,500 new cases of renal cell carcinoma (RCC) are diagnosed annually in the UK, and about a third of these cases initially present with cancer that has spread to other parts of the body (non-localised or metastatic). Non-localised RCC has significantly worse 5-year survival outcomes compared with localised disease. The treatment options for patients […]

read more

Cytoreductive surgery with immunotherapy for kidney cancer patients

In this video clip, Professor Eric Jonasch, Medical Oncologist, Division of Cancer Medicine at MD Anderson Cancer Center, University of Texas, Houston, speaks about the role of cytoreductive surgery along with immunotherapy for patients who have metastatic renal cell carcinoma (RCC). Watch the video on Practice Update here

read more

Radical versus partial nephrectomy and subsequent hypertension risk

In a recent study, the data from a database were analysed retrospectively to evaluate the onset or worsening of high blood pressure (hypertension) following partial versus radical nephrectomy. 3106 patients who did not have hypertension before nephrectomy had an increased risk of developing hypertension after radical nephrectomy. In 6250 patients who already had hypertension, radical […]

read more

Stereotactic radiosurgery is successful for RCC brain metastases

A recent study of 362 patients with brain metastases from renal cell carcinoma (RCC) were treated with stereotactic radiosurgery to remove the metastases. The researchers concluded that stereotactic radiosurgery is highly effective in patients with brain metastases from RCC, and concomitant use of tyrosine kinase inhibitors (TKIs), such as sunitinib and pazopanib, does not suggest […]

read more

ASCO 2019: Analysis of CARMENA trial results using IMDC risk groups

The results from CARMENA, a randomised phase III clinical trial to assess the importance of surgery to remove the kidney (nephrectomy) in people with metastatic kidney cancer, have been re-analysed and were presented at the 2019 American Society of Clinical Oncology (ACSO) annual meeting in Chicago this week. The original results showed that many people with […]

read more

Percutaneous cryoablation for stage T1b tumours

A recent study published in Cardiovascular and Interventional Radiology this month looked at the use of percutaneous cryoablation for stage T1b (4.1-7.0 cm) renal cell carcinoma (RCC). This non-invasive technique, which involves ‘freezing’ the tumour using fine needles inserted through the skin (percutaneous), has not yet been widely adopted. The current study investigated the safety, […]

read more
Showing 1 to 10 of 37 results
  TOP